As demand for immunoglobulin therapies grows across rare autoimmune diseases, manufacturers must expand plasma fractionation capacity while maintaining strict GMP and viral safety standards. This case study shows how Boccard delivered a large-scale, integrated immunoglobulin production facility designed to support long-term IVIg supply.
Modern process solutions enable the safe, efficient, and GMP-compliant production of oncology drugs. Thanks to advanced pharmaceutical technologies, it is possible to scale up production while maintaining the highest quality and full process control.
From June 16–18, 2026, Boccard will take part in PCI Days 2026, held at the EXPO XXI Exhibition Center in Warsaw.
As global diabetes prevalence continues to rise, insulin production must scale while meeting strict GMP and sterility requirements. This case study explores how industrial insulin manufacturing is designed, from biotechnology to aseptic formulation, and how Boccard supported a major producer in reinforcing formulation capacity.
Boccard in Latin America at Expo Pack 2026 | Process & Life Sciences Solutions For over thirteen years, Boccard has been strengthening its presence in
Boccard at the Pitch Sessions during CEBioForum 2026 Meet the innovators shaping the future of life sciences. At this year’s CEBioForum 2026, taking place onApril
As global diabetes prevalence continues to rise, insulin production must scale while meeting strict GMP and sterility requirements. This case study explores how industrial insulin manufacturing is designed, from biotechnology to aseptic formulation, and how Boccard supported a major producer in reinforcing formulation capacity.
As demand for GLP‑1 therapies grows in obesity and Type 2 diabetes care, manufacturers must rapidly scale production while meeting strict GMP requirements. This case study shows how Boccard delivered a robust and scalable GLP‑1 production line.
Discover how lactic acid for food ingredients (E270) is produced by fermenting molasses with lactic‑acid‑producing microorganisms, then readied for scale with inline pH and DO, CIP/SIP and hygienic utilities in a compact footprint. TEKINBIO™ with Track Advance delivers optimised aeration, mixing and thermal control with recipe governance and lot‑to‑lot comparison, creating a reproducible and traceable path to industrialisation.
Discover how cosmetic biocarriers are produced through fermentation: combining biosurfactant inputs with biopolymer matrices to encapsulate actives and deliver controlled release. Boccard supplied 2×300 L pilot bioreactors as plug‑and‑connect skids (gas handling, dosing, CIP/SIP), creating a reproducible pilot environment that simplifies recipe iteration and scale‑up. With TEKINBIO™ and Track Advance, teams gain tighter control of aeration, mixing, and temperature, plus lot‑to‑lot comparison for reliable industrialisation.
